Huge European Parliament majority votes to adopt the SPC manufacturing waiver

17 April 2019

The European Parliament today voted overwhelmingly with 572 Members of […]

‘Together for Health’: Medicines for Europe launches election manifesto to deliver on equitable patient access

3 April 2019

Medicines for Europe has launched its vision for pharmaceutical policy […]

Accelerating the biosimilar medicines access journey through benefit-sharing

28 March 2019

Biosimilar medicines have significantly increased equity of access to important […]

Major challenges in the Intellectual Property (IP) environment for pharmaceuticals debated at Medicines for Europe Legal Conference

27 March 2019

The SPC manufacturing waiver, which will put an end to […]

Joint Press Statement of the Inter Associations Initiative (IAI) Pharmaceuticals in the Environment Task Force (AESGP, EFPIA, Medicines for Europe) – European Union Strategic Approach to Pharmaceuticals in the Environment

12 March 2019

Report calls for better environment to improve patient access to value added medicines

26 February 2019

A new report launched today lays out clear recommendations to […]

Medicines for Europe applauds compromise on SPC manufacturing waiver

14 February 2019

Today, the European Council, Parliament and Commission agreed a compromise […]

New safeguards for patient safety as Falsified Medicines Directive comes into force

8 February 2019

The EU Falsified Medicines Directive was adopted in 2011 to […]

SUPPORT a comprehensive SPC manufacturing waiver: for patient access, sustainable healthcare and manufacturing jobs

7 February 2019

SPC manufacturing waiver cannot be derailed by foreign vested interests

7 February 2019

Medicines for Europe calls on the European Council, Parliament and […]